Jonathan Langley Appointment
ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience...
Jonathan Langley Appointment
ATXA Therapeutics looks to raise $30m to secure regulatory approval
Publication of preclinical findings for ATXA Therapeutics' NTP42
100 Hot Start Ups.
ATXA & PAH- Hope attend ERS Congress 2019 in Madrid
ATXA attends the ESC Congress 2019 in Paris
ESC Congress Paris 2019
Experimental and Molecular Pathology
New paper on thromboxane receptors in prostate inflammation published in Experimental and Molecular